Prestige Biopharma posts positive Phase 3 data for Avastin biosimilar

Prestige Biopharma said its Phase 3 SAMSON-II trial met the primary endpoint for HD204, the company’s proposed biosimilar to Avastin (bevacizumab), in adults with advanced non-squamous non-small cell lung cancer. In the 625-patient, double-blind, multicenter study across 15 countries, overall response rate at week 18 was 48.7% with HD204 and 46.5% with Avastin, with efficacy estimates falling inside the prespecified equivalence margin. The company also said progression-free survival, overall survival, safety, and immunogenicity were comparable, and that it’s now advancing regulatory pathways for the product. HD204 has been in development for years, and Prestige already has a commercialization partnership with Intas and Accord Healthcare covering the US, Europe, Canada, and other markets. (prnewswire.com)

Why it matters: For veterinary professionals, this is mostly a market and regulatory signal rather than a practice-changing development. Bevacizumab is a major oncology biologic, and the biosimilar category is already crowded in human medicine, with multiple FDA-approved Avastin biosimilars on the market. More broadly, the human biosimilars pipeline keeps expanding beyond oncology too, with recent FDA approval of Teva’s denosumab biosimilar Ponlimsi and FDA/EMA acceptance of Teva’s omalizumab biosimilar filings, both supported by analytical and clinical packages showing comparable efficacy, safety, and immunogenicity to their reference products. Another late-stage entrant like HD204 could add more pricing pressure and reinforce the broader trend that biosimilars are becoming normalized tools for managing treatment costs and access, which matters to veterinarians tracking translational oncology, comparative medicine, hospital purchasing trends, and pet parent expectations shaped by human specialty care. (fda.gov)

What to watch: Watch for full data presentation, regulatory filing timing in the US and Europe, and whether Prestige gives a clearer commercialization timeline with Intas and Accord. More broadly, continued biosimilar approvals and filing acceptances across categories such as denosumab and omalizumab will help show how durable this regulatory and market momentum really is. (prnewswire.com)